Nanosized Particles Assembled by a Recombinant Virus Protein Are Able to Encapsulate Negatively Charged Molecules and Structured RNA

Hemalatha Mani,Yi-Cheng Chen,Yen-Kai Chen,Wei-Lin Liu,Shih-Yen Lo,Shu-Hsuan Lin,Je-Wen Liou

DOI: https://doi.org/10.3390/polym13060858

IF: 5

2021-03-11

Polymers

Abstract:RNA-based molecules have recently become hot candidates to be developed into therapeutic agents. However, successful applications of RNA-based therapeutics might require suitable carriers to protect the RNA from enzymatic degradation by ubiquitous RNases in vivo. Because of their better biocompatibility and biodegradability, protein-based nanoparticles are considered to be alternatives to their synthetic polymer-based counterparts for drug delivery. Hepatitis C virus (HCV) core protein has been suggested to be able to self-assemble into nucleocapsid-like particles in vitro. In this study, the genomic RNA-binding domain of HCV core protein consisting of 116 amino acids (p116) was overexpressed with E. coli for investigation. The recombinant p116 was able to assemble into particles with an average diameter of approximately 27 nm, as visualized by electron microscopy and atomic force microscopy. Measurements with fluorescence spectroscopy, flow cytometry, and fluorescence quenching indicated that the p116-assembled nanoparticles were able to encapsulate small anionic molecules and structured RNA. This study demonstrates methods that exploit the self-assembly nature of a virus-derived protein for nanoparticle production. This study also suggests that the virus-derived protein-assembled particles could possibly be developed into potential carriers for anionic molecular drugs and structured RNA-based therapeutics.

polymer science

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an effective method to protect and deliver negatively - charged molecules and structured RNA. Specifically, the researchers used nanoparticles self - assembled from recombinant viral proteins (domain 1 of HCV core protein, namely p116) to explore whether these particles can encapsulate negatively - charged small molecules and structured RNA, thus serving as potential drug carriers, especially for RNA - based therapeutics. Since RNA is easily degraded by ubiquitously existing RNase in vivo, appropriate carriers are required to protect RNA in order to improve its stability and therapeutic effect. This study verified the encapsulation ability of p116 - assembled nanoparticles for negatively - charged molecules and structured RNA through techniques such as fluorescence spectroscopy, flow cytometry and fluorescence quenching experiments, providing experimental evidence for the development of novel drug - delivery systems.